Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
In this article:
Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.
Advertisement